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Abstract 
It is an open question as to whether blockchains can become an integral part of health care management in the US. On the one hand, 
there are the advocates of blockchains who see them as empowering patients to capture property rights to their medical records in a 
secure, encrypted, and portable form. On the other hand, there are blockchain critics that see the opportunities offered in health care 
as little different from those offered in other industries, viewing a blockchain structure as one that may reduce administrative and 
transaction costs, with little thought given to the potential of blockchain platforms to support a range of health technology assessment 
activities. While previous commentaries have pointed to this potential, the obstacles offered by the absence of clearly defined property 
rights and the absence of a market for DNA profiles have not been explored. The case put forward here is that any expectation that a 
blockchain as a ‘one-stop-shop’ for the interrogation of personal health records alone is unlikely to succeed. Apart from property rights 
effectively blocking this business model the blockchain vendor should consider targeted value added activities. At best, only a subset 
of records has the possibility of being transferred, with ongoing concerns regarding their quality and scope. This does not mean that 
the blockchain software model should be rejected. Far from it. The blockchain as a health technology assessment platform has the 
potential to support added value activities which not only improve the process of care and reduce costs and improve efficiencies, but 
also provide an ideal framework for property rights assignment. This opens the door to incentives and the monetization of value added 
health data by patients and providers, capturing rents that are at the moment expropriated by third parties. Critical issues are not only 
property rights and creation of a market place, but the ability to link and incentivize patients and their providers to support active 
blockchains to generate value added.  
 




Will blockchain technology transform US health care? Will the 
presumptive claims for blockchains as platforms to support 
health technology assessment, be recognized and adopted by 
patients, providers and health care systems? To what extent will 
the opportunity presented by blockchains, as opposed to 
existing and widely adopted patient record software systems, 
support the potential for property rights transfer and the 
marketing of health data under smart contracts to third parties?  
 
The purpose of this commentary is to consider whether there is 
market potential for blockchains as a software platform to 
support health technology assessment? Recently published 
commentaries in INNOVATIONS in Pharmacy have explored the 
potential role of blockchains as one software platform option in 
such assessments1,2,3. The arguments presented in these 
commentaries pointed to an unmet need for the evaluation and 
replication in target patient populations of claims for new and 
existing products. The purpose of this commentary is to argue 
that the benefits of blockchain technology are more likely to be 
achieved if the vendor, not only has an appropriate  
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management structure in place to support data access and 
monetization, but that the vendor adopts an active rather than 
a passive model of data assembly. 
 
A Secure Medical Record 
To date, there seems little evidence as to whether or not there 
is a demand for a secure, portable and readily accessible 
blockchain driven medical record. Rather, it seems to have been 
assumed: (i) that patients are dissatisfied with current medical 
record storage and access protocols and (ii) that there is a 
groundswell of opinion in favor of mandating the transfer of 
medical record ownership to patients. Given these assumptions, 
the advocates of blockchains have then leapt to the conclusion 
that, following experience and proposed innovations in banking 
and finance with their specific demands for security, encryption, 
validated transactions and access, blockchains are the obvious 
solution for a medical record ‘one-stop-shop’. The retail aura 
being supported by the presumed ability and interest of patients 
to monetize their medical record by offering smart contracts to 
third parties. 
 
If our criteria are for a secure yet portable and accessible on 
demand medical record repository, then blockchains are 
certainly a solution. There is, however, the need to distinguish a 
blockchain as a secure record repository from a blockchain as an 
active platform that can not only provide a secure transaction 
ledger for medical encounters but support value added 
interventions and health technology assessment protocols; a 
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transaction ledger which can not only record medical 
encounters but can support commercially viable research and 
assessment activities.   
 
Once the question of value added activities in health technology 
assessment are brought into the picture, then we can consider 
moving beyond the passive blockchain model as a lifetime 
record of encounters within a range of medical environments – 
current and previous provider primary care visits, referrals, 
urgent care visits, emergency room visits and hospitalizations - 
to one where the elements of a medical record available 
through the blockchain are only one part of a platform that can 
capture additional real-time data elements through disease 
specific value added activities. With property rights assigned, 
these complementary data elements can then offer the promise 
of smart contracting and monetization.  
 
Some Pertinent Questions 
A number of questions have to be addressed if this vision of an 
active blockchain is to be realized. Who owns the medical 
record? Are property rights a potential barrier to effective 
record transfer and aggregation over target patient 
populations? How do we transfer grandfathered medical 
records that may go back over decades? Is the data transfer 
protocol for these various medical locations applicable to them 
all? What permissions would have to be obtained? Does the 
blockchain capture in one time-stamped verified transaction 
text, video and scans (and even billing) for an entire encounter 
such as a two-day hospitalization? How do we judge the quality 
of the data that are transferred to the blockchain? Does the 
blockchain support effective medical record search protocols? 
Can it include misdiagnoses that are later revisited? Are the 
transaction ledgers complete? Does the blockchain include the 
complete list of prescribed pharmaceuticals with brand/generic 
names, dosage, formulation number of tablets and National 
Drug Code? Are there precise markers such as ICD-10-CM codes 
and CPT codes? Does the blockchain include an algorithm to 
translate prior ICD-9-CM codes to ICD-10-CM codes (the latter 
mandatory from February 2014)? Does the blockchain provide 
links to ICD-10-CM text titles and whether these are billable 
codes?  
 
Apart from raising questions as to the coverage of a blockchain 
medical record, the quality of the data and the completeness of 
the record, any attempt to identify specific data elements may 
involve an unacceptable search time as each prior locked 
transaction (and there will be hundreds if. If the blockchain is 
seen only as a portable yet passive record, is it able to support 
medical emergencies outside of the patient’s primary care 
environment? Will the attending physician and staff in an 
emergency room be able to review the medical record in time? 
More to the point: what does the blockchain offer over and 
above present admission protocols (e.g., screen-based 
questionnaires with default algorithms) which are designed to 
accommodate admission vitals and record the visit? What 
evidence is there that access by a treating physician at a remote 
site to the patient’s blockchain record will materially improve 
outcomes? 
 
Certainly, blockchains are an elegant solution. But this is only a 
presumption; is it a solution in search of a problem? We need to 
think more carefully as to what blockchains offer, obstacles to 
their endorsement by health systems, patients and providers, 
and the contribution they can make to unmet needs in health 
technology assessment. After all, if the rallying cry is for record 
ownership and monetization, a reasonable question for patients 
is the likely return from data ownership. If it is only in the tens 
of dollars it may be less than attractive.  
 
Blockchain Recruitment 
If we think about a vendor focused on developing a viable 
blockchain product, then the first question to ask is: how are 
patients to be recruited to the blockchain? There are two 
avenues: a patient can enroll unilaterally, and then request the 
blockchain vendor to facilitate transfer of their medical records 
to the blockchain, or the blockchain vendor can contract with a 
provider to act as an intermediary in recruiting practice patients 
to the blockchain. This latter recruitment avenue is to be 
preferred, as it not only supports a more rapid and focused 
recruitment of patients, but that it also sets the stage for future 
value-added technology assessment activities that jointly 
involve patient and provider. 
 
Unless the provider wishes to be actively involved in technology 
assessment, the contribution of blockchains as a monetized 
record resource will be limited. If the focus is on creating 
blockchain value through investing in health technology 
assessment activities, then the provider is a critical part of the 
ability to capture and monetize the assembled data. Certainly, 
the provider may facilitate transfer of medical records to the 
blockchain, but these records may be, at best, a secondary 
source of data. If the focus within specific disease areas is, for 
example, response to therapy, there are more than likely a 
number of endpoints not captured in the medical record. At the 
same time, searching the medical record for endpoints may be 
frustrating, not only due to the lack of standardized responses, 
but the difficulties of trying to identify responses through search 
algorithms.  
 
A continuing focus in health technology assessment is mining of 
de-identified patient records. While there is substantial 
literature demonstrating the ability to draw substantive 
conclusions on therapy impacts from de-identified medical 
records (e.g., the UK Clinical Practice Research Datalink and       
its earlier incarnation as the General Practice Research 
Database4) the limitation is these data are assembled after the 
data bus has left the depot. The blockchain platform allows, to 
extend the metaphor, value added activities in data assembly to 
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populate the bus with ‘a better class’ of passenger. It is possible 
to generate a database of de-identified records and apply search 
and artificial intelligence to, literally, tease out responses. A far 
more robust approach is to see the blockchain as a vehicle to 
support structured mining of therapy response with inputs from 
both the provider and the patient.. This allows, not only for 
agreement on the assignment of property rights between the 
provider and patient but a firm basis for monetization; a 
structured interrogation of data that have been quality 
assessed. 
 
 Property Rights 
A question which has not been addressed fully in the blockchain 
literature is the role of property rights to medical records. There 
are clearly expectations by a number of blockchain developers 
that blockchains have a role as a secure yet portable lifetime 
repository for a patient’s medical records; a medical record 
‘one-stop-shop’. Certainly, blockchains offer this potential. 
Unfortunately, the question of property rights to those records 
may torpedo this ‘one-stop-shop’ vision. The question then 
arises: if blockchains are able only to capture and monetize 
through smart contracts medical records to which the patient 
has undisputed property rights, is it possible to consider 
blockchains as a software platform with a wider yet 
complementary role, a role which also allows smart contracting 
and monetization? 
 
Certainly, there are widespread concerns over the security of 
medical records. Instances abound on hacking of systems and 
the ransoming of re-access, with the UK National Health Service 
hospital data a well-established and ongoing target. The fact 
that security can be breached and patient medical records put 
at risk is not, in itself, a justification for a jump to blockchain 
software as the ‘one size fits all’ solution. There are a number of 
unresolved questions. Are we to consider only the security of 
patient health records? Is there a demand by health systems to 
move to a blockchain solution for record storage (scalability 
issues)? Are blockchains to be seen only as a way of reducing 
health system administrative and transaction costs? United 
Health care seems to take this point in proposing a pilot project 
to control better provider records and contacts in an insurance 
system. Should a health care system capture individual patient 
encounters in a blockchain? Does this mean we will have two 
blockchains: one for health systems (and individual providers) 
that captures stores, encrypts, validates and timestamps all 
patient encounters in that system, possibly linked to their 
electronic medical record software system, with another 
blockchain for individual patients? Consider a matrix of 
encounters (the individual cells of the matrix) with health 
providers. The rows of the matrix are defined for individual 
patients while the columns capture the health systems where 
encounters may occur. Under the health system blockchain, 
each column of the matrix represents the encounters of patients 
with the particular provider while the rows capture the 
encounters of an individual patient with the various providers. 
This latter row entry defines the electronic medical record or the 
capture of records by the individual patient’s blockchain. Each 
record element of the provider-patient matrix has property 
rights. These may be unambiguously assigned to the patient or 
provider, or may be in a ‘fuzzy’ limbo where property rights are 
yet to be adjudicated. If these row data elements, for each 
patient, are attempted to be transferred to the blockchain but 
are blocked or delayed, then the data set may be incomplete 
and fragmented.  
 
In single payer health systems in countries such as Australia, 
New Zealand and the UK the property rights to medical health 
records are typically claimed by the government. If blockchains 
are to be advocated, then the patient’s rights would be limited. 
Unless there was an agreement to surrender property rights in 
favor of the patient, then there would be no opportunities for 
smart contracting and monetization. More to the point, unless 
lifetime record security and portability were considered a 
concern by both patients and system managers, there would be 
no incentive to abandon the present software environment.  
 
Interestingly, the focus on who owns whose data in our 
blockchain ecosystem has been on the patient, versus the 
provider or health system. Once the matrix picture is 
considered, the property rights scope opens to the possibility of 
conflict over property rights between providers. Does, for 
example, a primary care provider (PCP) who refers a patient to 
a cardiologist, have property rights over the cardiologist’s 
record? Including, even, the summary report typically sent to 
the PCP? Can the PCP assume property rights and, without 
reference to the cardiologist, transfer these to the patient? All 
challenging questions that need to be addressed and answered! 
 
As noted in previous commentaries, there is no national 
agreement in the US on medical record property assignment1, 2. 
This is within the jurisdiction of individual states. New 
Hampshire is the only state that has assigned property rights to 
the patient; outside of New Hampshire some 21 jurisdictions 
have property rights assigned to the provider, with the added 
complication that patients typically assign property rights to 
their provider, with providers also assigning their rights to 
insurers and other potential vendors of medical data. Given this, 
and the reluctance of many health systems to relinquish rights 
in which they may have a monetary interest with sales to third 
parties, it would be unwise for a blockchain developer to 
assume that a patient has undisputed property rights. As most 
developers have limited resources, it is unlikely that they would 
have the inclination to address this issue. They may live in the 
hope that the federal government might intervene and override 
state and commercial interests. This is unlikely.  
Unfortunately, the absence of agreed and well-defined property 
rights to the records that make up a patient’s health history 
means, irrespective of any technical issues associated with 
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record transfer and search, that the vision of a blockchain 
medical record capturing a patient’s complete medical history 
and transforming this into a viable commercial product is 
unlikely to be realized. Not only would the record set be 
incomplete, there would be no necessary concordance between 
patients over which data elements from which provider are 
actually captured in the individual blockchains. The more 
practical barrier to a ‘complete’ blockchain record is the 
presence of substantial commercial interests in stand-alone 
health records. Undoubtedly, there would be pushback on 
property rights assignment and monetization; an ongoing 
debate that would be unlikely to be resolved in the near term. 
Claims that patients have an inherent right to their records, and 
the prospects that ownership may support monetization, may 
simply be ignored. 
 
The attraction of challenging property rights and eliminating 
erecting barriers to market entry to protect revenue streams 
can be seen in the case of DNA profiles. There are now a number 
of vendors for DNA riding on the back of interests in family 
genealogy. Typically, an individual will submit a specimen ‘spit’, 
this is analyzed and a report sent to the client. The cost can 
range from the low to mid hundreds of dollars. Clients are given, 
in some cases, the option of allowing access to their de-
identified DNA profile by third parties. In the case of 23andMe, 
a leading vendor, a recent agreement with GlaxoSmithKline 
(GSK), a leading pharmaceutical company, was for the transfer 
of millions of DNA records for the sum of $300 million. Under 
this business model the client pays for the DNA profile (it covers 
the costs of production) while contributing to the vendors 
bottom line (Profit line 1). In selling the DNA profiles to GSK, 
23andMe establishes Profit line 2. At no stage is the client 
informed of potential monetization of their DNA profile. The 
revenue stream from GSK is pure rent. In abrogating property 
rights, the client is out of pocket. First, through meeting the 
costs of production of the DNA and contributing to the vendors 
bottom line while, second, failing to capture any part of the rent 
accruing from GSK to the vendor. 
 
The client loses out because of the abrogation of property 
rights. The rights accrue to the DNA vendor who can extract as 
much rent as possible through contracting the DNA profiles 
(perhaps multiple times for each profile, to different third 
parties). The client has no idea of revenue (or DNA royalties) 
forgone because of the absence of a market to give signals as to 
the price of DNA profiles (which may not all have the same 
market value). The only way to avoid this is for the client to insist 
on ownership of the DNA profile. The profile would be lodged 
on the blockchain with the DNA vendor confirming that the 
profile is not retained in their records. At the same time, the 
client should insist that the DNA vendor, and there may be 
competition between vendors, should pay the client for their 
profile. Once one DNA vendor offers to pay for profiles, the rest 
will fall into line. The only remote exception being where the 
vendor warrants not selling to third parties. The client contracts 
with the DNA vendor as agent for third party use with a market 
price established for sale to a third party to be determined, 
when the DNA vendor contracts with a third party. Again, if a 
market is established, third parties would be expected to 
compete for vendor contracting. The alternative scenario is 
where the blockchain vendor acts as agent for the individual in 
monetizing their DNA for third parties under smart contracts.  
 
It is not surprising in the ancestor-focused world of DNA profiles, 
vendors attempt not only to retain property rights to client 
profiles, but simultaneously avoid provision of information on 
the imputed market value of the profile. This value may be 
derived from the ‘mining of the profile’ by a third party 
pharmaceutical manufacturer and potentially augmented if 
linked to other databases. Not surprisingly again are efforts by 
vendors such as 23andMe, to set up artificial barriers to market 
pricing, profile dissemination and capture in platforms such as 
blockchains. Giving a concrete example, the imputed value or 
shadow price of a profile with nominated characteristics is 
$1,000 and the special summer sale DNA profile offer is $100 
(with a profile production cost to the vendor of $20) then the 
client gives away not only the $1,000 of pure rent (less 
contracting costs) and any fee paid by the vendor to the patient 
for the right to undertake the DNA assay (which will vary with 
the profile). Under present arrangements, the return to the 
vendor is $1,080 for the profile, while nothing accrues to the 
client. 
 
Value Added and the Blockchain Record 
If the concern is with the completeness of the medical record, 
then the scenario where the provider acts as the agent or 
intermediary in patient recruitment might actually facilitate 
transfer of property rights.  The provider sees it is in the 
interests of both parties for medical records from the practice 
to be copied over to the blockchain and property rights 
recognized by both parties. This shared interest in generating as 
complete a blockchain record as possible can also extend to 
value added activities. As noted above, if disease specific 
platforms for assessing the value of competing drugs and 
devices are built, then there is the opportunity for patients and 
providers to co-operate in both evaluating the process of care 
and response to therapy, as well as facilitating monetization to 
third parties.  
 
Unless property rights can be assigned and enforced through 
smart contracts, claims that patients can take control of their 
medical records, transfer them to a blockchain allowing them to 
monetize any record through smart contracts are likely non-
starters.  Patients would only have only the ability to contract 
for those records where an unambiguous property right exists. 
This does not mean that they do not have the right to view their 
records and share these with other medical professionals as the 
need or emergency arises. In many instances this is already 
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feasible, at least for the PCP record, which often includes 
records from referrals and encounters with urgent care, 
emergency rooms and hospitals. Some specialist providers now 
provide similar access, with hospitals not far behind. The point 
remains, however, that the records are fragmented and typically 
non-interoperable.  
 
If property rights to the existing medical record (and records 
capturing future encounters) block the ability to create a 
blockchain record analogue, the blockchain vendor faces the 
risk of commercial failure. Patients may be unwilling to enroll in 
the blockchain if they see little chance of effective monetization 
of their records. The blockchain will fail to achieve a ‘required’ 
minimum number of enrollees to support, even with incomplete 
or fragmented medical records, viable commercialization. 
Potential third-party clients such as pharmaceutical 
manufacturers will have little interest in the data and 
opportunities to evaluate product performance.  
 
Accepting the proposition that blockchains that rely exclusively 
on transferred medical records face an uncertain commercial 
future, the question then becomes one of whether the active 
blockchain business model is feasible. The blockchain model 
could support the creation of commercially viable data sets, 
with a reasonable probability of enrolling a minimum number of 
patients in a relatively short time frame to ensure commercial 
viability. 
 
The appeal of the active blockchain model is that it provides the 
opportunity for the blockchain vendor to work with both the 
patient and the provider, while creating incentives structured 
for both participants, including the opportunity to generate 
additional practice revenue for the provider. Data collected in 
added value applications for chronic disease states, to give one 
example, would be structured to allow for ease of interrogation 
through data dictionaries. Data elements can be selected from 
the medical record and linked to the structured data, with the 
added advantage of access to a more complete medical record 
set for that particular application. 
 
The viability of the value-added business model depends on a 
number of factors. First and foremost is to demonstrate the 
ability of the blockchain vendor, who will presumably be 
coordinating the value added data assembly, to meet not only 
required professional standards in health technology 
assessment but the ability to target providers and provider 
groups to demonstrate the benefits of a blockchain. Second, the 
blockchain vendor must demonstrate that the proposed 
software platform meets the required standards for data 
transfer, storage, smart contracting and monetization. Third, as 
the role of the proposed platform is to support patients and 
providers in the long term, there must be confidence in the 
ability of the vendor to provide such support. Finally, the vendor 
should have a viable business strategy to roll out the blockchain. 
This is crucial, as the ability of the blockchain vendor to exploit 
the opportunities in health technology assessment (detailed in 
previous commentaries) have to be demonstrated to potential 
clients; not least of whom are providers and health system 
managers who may consider contracting, hopefully in the long 
term, with the a blockchain vendor.  
 
Conclusions: First Steps to a Viable Active Blockchain 
It would be foolish to think as noted in the title of this 
commentary, that patients, providers and health system 
managers will flock to a blockchain vendor. If the focus is on 
health technology assessment, previous commentaries have 
pointed to the range of assessment activities that could be 
undertaken with a ‘mature’ blockchain ecosystem in place in a 
health system. The challenge for a blockchain vendor is twofold: 
(i) targeting the most likely candidates for establishing a 
blockchain to support health technology assessment and (ii) 
demonstrating the viability of a blockchain in terms of its 
technical performance and its consequent ability to generate a 
substantive revenue stream, while demonstrating true 
downstream (outcomes, efficiency, cost savings, etc.) value for 
the client involved.  
 
As described in previous commentaries, the blockchain should 
be seen as an umbrella (or exoskeleton) for supporting data 
generated from: (i) the transferred electronic medical records or 
links to the established record and (ii) from added value 
targeted interventions in specific disease states that generate 
additional data elements. The critical issue is the ability to 
generate data that not only support more effective care but also 
serve as a potential revenue source to third parties. This has yet 
to be demonstrated even though potential clients will see this 
as a sine qua non, not only of engaging with a blockchain system 
but of data transfer to that system. In summary, why go to the 
problem of dealing with property rights if the data elements that 
can eventually be transferred to generate the fragmented 
medical record into blockchain are impossible to identify and 
link to other data elements.  
 
The creation of value added data goes to the heart of questions 
promoting a blockchains value in health technology assessment: 
the ability, within target patient groups to meet unmet medical 
needs in the comparative evaluation of healthcare interventions 
and the response of patients to treatment interventions in real 
world environments. There are any number of disease states 
where the data for medium to long-term response is either 
limited or absent. This would be the major selling point to health 
systems and providers: putting in place a platform which allows 
a more focused assessment of care, tracking outcomes, 
evaluating competing drugs and devices, while at the same time 
meeting quality standards mandated by assessment agencies. 
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